IQVIA and Veeva’s Strategic Alliance Spikes Trading Volume 41.85% as Stock Jumps into Top 500 List

On August 18, 2025, IQVIA (NYSE: IQV) closed with a 0.76% gain, trading on $260 million in volume, a 41.85% surge from the prior day. The stock’s performance followed the announcement of a strategic global partnership with Veeva Systems, marking a resolution to pending legal disputes and enabling integrated use of their clinical and commercial tools. The collaboration allows customers to combine IQVIA’s data and analytics with Veeva’s software platforms, streamlining workflows in areas like master data management, AI-driven analytics, and clinical trial execution.

The partnership establishes master data and third-party access agreements, enabling seamless integration of IQVIA’s insights with Veeva’s solutions such as Veeva Network, Nitro, and EDC. IQVIA also joined Veeva’s CRO Clinical Data Partner program, enhancing its ability to accelerate database builds and data delivery for clients. Executives from both firms emphasized the potential for improved efficiency in clinical development and commercial operations, citing combined strengths in AI, technology, and domain expertise.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to now delivered moderate returns. The total profit grew steadily over the period, with a few fluctuations due to market dynamics. As of the latest data, the strategy's total profit stands at $10,720.